The Life Sciences team advised Triumvira Immunologics on the intellectual property aspects of its $100 million Series A financing.
Triumvira is a clinical-stage company developing unique, non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors.
The Series A featured new investors, including significant participation from B Capital Group, along with ATEM Capital, the Myeloma Investment Fund, the Multiple Myeloma Research Foundation’s venture philanthropy subsidiary, and others, joined by significant participation from existing investors, Leaps by Bayer, the impact investment unit of Bayer AG, and Northpond Ventures.
The Goodwin team was led by Sabrina Poulos.
For more details, read the press release.